Trial Profile
A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 25 Jun 2013 Secondary results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2013 Primary results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 27 Jan 2012 Actual end date changed from Jan 2011 to Feb 2011 as reported by ClinicalTrials.gov.